Table 2 The comparison of fibrin clot proprieties.
Variable | All patients (n = 310) | Non-ATE patients (n = 289) | Patients with ATE (n = 21) | P | Patients without recurrent VTE and ATE during follow-up (n = 211) | Patients with recurrent VTE*(n = 83) | Patients with ATE (n = 16) | P |
---|---|---|---|---|---|---|---|---|
Ks, 10–9 cm2 | 7.4 (6.5–7.9) | 7.4 (6.6–8) | 6.8 (6.4–7) | 0.036 | 7.5 (6.9–8.1) | 6.6 (6.1–7.3) | 7 (6.6–7.5) | < 0.001† |
Lag phase, s | 43 (39–46) | 43 (39–46) | 43 (37–46) | 0.58 | 44 (40–47) | 40 (35–44) | 43.5 (37.5–46) | < 0.001† |
ΔAbs | 0.81 (0.77–0.85) | 0.81 (0.77–0.85) | 0.83 (0.8–0.86) | 0.09 | 0.8 (0.76–0.85) | 0.83 (0.78–0.87) | 0.83 (0.8–0.87) | 0.043† |
D-Dmax, mg/L | 4.07 (3.68–4.39) | 4.07 (3.68–4.34) | 4.31 (3.8–4.42) | 0.17 | 4.07 (3.64–4.32) | 3.98 (3.69–4.41) | 4.32 (4.15–4.46) | 0.05 |
D-Drate, mg/L/min | 0.072 (0.068–0.079) | 0.072 (0.068–0.079) | 0.077 (0.071–0.083) | 0.017 | 0.072 (0.069–0.08) | 0.069 (0.066–0.073) | 0.077 (0.071–0.083) | < 0.001† 0.002‡ |
CLT, min | 86 (74–99) | 86 (74–99) | 82 (70–95) | 0.41 | 81 (71–94) | 100 (90–108) | 75 (68.5–89) | < 0.001†‡ |